These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21461169)

  • 1. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
    Looyenga BD; Cherni I; Mackeigan JP; Weiss GJ
    Transl Oncol; 2011 Apr; 4(2):59-70. PubMed ID: 21461169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
    Guo R; Chen X; Wang T; Zhang Z; Sun J; Shu Y
    BMC Cancer; 2011 Mar; 11():90. PubMed ID: 21366910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.
    Kono SA; Marshall ME; Ware KE; Heasley LE
    Drug Resist Updat; 2009; 12(4-5):95-102. PubMed ID: 19501013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.
    Singh N; Jindal A; Behera D
    World J Clin Oncol; 2014 Dec; 5(5):858-64. PubMed ID: 25493223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
    Burotto M; Ali SA; O'Sullivan Coyne G
    Expert Opin Drug Saf; 2015 Jan; 14(1):97-110. PubMed ID: 25345687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to EGFR targeting therapies in lung cancer.
    Watzka SB; Posch F; Hochmair M; Setinek U; Köstler WJ; Müller MR
    Minerva Chir; 2011 Oct; 66(5):483-94. PubMed ID: 22117213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
    Xu Y; Liu H; Chen J; Zhou Q
    Cancer Biol Ther; 2010 Apr; 9(8):572-82. PubMed ID: 20404520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
    Mojtabavi Naeini M; Tavassoli M; Ghaedi K
    Gene; 2018 Aug; 667():62-69. PubMed ID: 29758295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Bar J; Onn A
    Clin Lung Cancer; 2012 Jul; 13(4):267-79. PubMed ID: 22154113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.